Galapagos delivers candidate drug in GSK alliance and receives

Galapagos delivers candidate drug in GSK alliance and receives
milestone payment 
MECHELEN, BELGIUM -- (Marketwire) -- 01/09/13 -- Galapagos  NV
(Euronext: GLPG) announced today  that it successfully delivered a
fifth pre-clinical candidate drug in its alliance with
GlaxoSmithKline (GSK) triggering a milestone payment to Galapagos. 
In 2006 Galapagos and GSK initiated a drug discovery and development
alliance to deliver  disease modifying  drugs for  GSK's global  R&D
organization.   In this
alliance Galapagos delivered a fifth
candidate drug. 
"Since  the  start  of  the  alliance  in  2006, Galapagos  has 
identified five
candidate  drugs of which two  have been in-licensed
by  GSK to date," said Onno
van de Stolpe, CEO of Galapagos.  "We
hope that more programs from this alliance
may enter the clinic." 
About Galapagos' immuno-inflammation alliance with GlaxoSmithKline 
Galapagos  and  GSK  initiated  an  alliance  to  discover  and
develop disease-modifying  drugs for  GSK's global  R&D organization 
in June 2006.  Subject to achievement  of certain milestone events
Galapagos  has the potential to receive
more  than EUR200  million in
 total milestone  payments, plus  up to double-digit
royalties  from 
GSK.   GSK  has  an  exclusive  option  to  further develop and
commercialize compounds from the alliance on a worldwide basis. 
About Galapagos 
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage
biotechnology company specialized in the discovery and development of
small molecule and antibody therapies with novel modes-of-action.  The
Company is progressing its JAK1 inhibitor GLPG0634, as well as one of
the largest pipelines
in biotech, with four programs in development
and over 30 discovery programs.
The Galapagos Group has over 800
employees and operates facilities in five countries, with global
headquarters in Mechelen, Belgium.  More info at: 
Galapagos forward-looking statements 
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could,"
"stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance
achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on
such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this
document to
reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based, unless
required by law or regulation. 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Galapagos NV via Thomson Reuters ONE 
Galapagos NV
Onno van de Stolpe
Tel: +31 6 2909 8028 
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Press spacebar to pause and continue. Press esc to stop.